Literature DB >> 8246447

Ultrastructural localization of heparin to human mast cells of the MCTC and MCT types by labeling with antithrombin III-gold.

S S Craig1, A M Irani, D D Metcalfe, L B Schwartz.   

Abstract

BACKGROUND: Mast cells derived from human skin and lung have been reported to produce heparin and chondroitin sulfate E proteoglycans. However, no information about the proteoglycans distribution among the different human mast cell types (MCTC and MCT) is available. Conjugates of antithrombin III-gold were used to assess the presence of heparin in both human mast cell subsets. EXPERIMENTAL
DESIGN: Thin sections of human and rodent tissues and dispersed cell preparations were labeled with the conjugate in the presence of saline, heparin, and chondroitin sulfates A and E and particle densities were measured over granules, perigranular regions, and extracellular space. Control sections were preincubated with heparinase, chondroitinase ABC, or buffer.
RESULTS: Labeling with antithrombin III-gold particles was detected in essentially all granules of human mast cells in skin (predominantly MCTC type), lung alveolar wall, and bowel mucosa (predominantly MCT type), but was negligible over human eosinophils. Consistent with the known distribution of heparin in rodent mast cells, strong labeling was observed over rat peritoneal connective tissue type mast cells, but not over mucosal mast cells in bowel mucosa of Nippostrongylus brasiliensis-infected rats (which contain chondroitin sulfate di-B) nor over mouse PT-18 mast cells (which contain chondroitin sulfate E). Mast cell labeling was preferentially blocked by exogenous heparin, and virtually abolished by heparinase but not chondroitinase ABC preincubation.
CONCLUSIONS: The data with rodent mast cells indicate that antithrombin III-gold labels cells that contain heparin, but not those that contain only over-sulfated chondroitin sulfates. Specificity of the procedure for detecting heparin is further demonstrated by inhibition of labeling after preincubation with heparinase and by competition with exogenous heparin. On this basis, we conclude that heparin is present in essentially all mast cells in normal skin, lung alveolar wall, and bowel mucosa. The presence of heparin in all human mast cells is different than for rodent mast cells, and probably accounts for the inability to clearly distinguish different human mast cell types from one another with histochemical stains based on proteoglycan content.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246447

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  9 in total

1.  Stem cell factor-dependent human cord blood derived mast cells express alpha- and beta-tryptase, heparin and chondroitin sulphate.

Authors:  G Nilsson; T Blom; I Harvima; M Kusche-Gullberg; K Nilsson; L Hellman
Journal:  Immunology       Date:  1996-06       Impact factor: 7.397

Review 2.  Mast cell proteoglycans.

Authors:  Elin Rönnberg; Fabio R Melo; Gunnar Pejler
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

3.  An histochemical approach to characterization of anionic constituents in mast cell secretory granules.

Authors:  E Skutelsky; T Shoichetman; I Hammel
Journal:  Histochem Cell Biol       Date:  1995-12       Impact factor: 4.304

Review 4.  Potential effector and immunoregulatory functions of mast cells in mucosal immunity.

Authors:  L L Reber; R Sibilano; K Mukai; S J Galli
Journal:  Mucosal Immunol       Date:  2015-02-11       Impact factor: 7.313

Review 5.  Mast Cell and Basophil Granule Proteases - In Vivo Targets and Function.

Authors:  Lars Hellman; Srinivas Akula; Zhirong Fu; Sara Wernersson
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

6.  Generation of anaphylatoxins by human beta-tryptase from C3, C4, and C5.

Authors:  Yoshihiro Fukuoka; Han-Zhang Xia; Laura B Sanchez-Muñoz; Anthony L Dellinger; Luis Escribano; Lawrence B Schwartz
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

7.  Determination of plasma heparin level improves identification of systemic mast cell activation disease.

Authors:  Milda Vysniauskaite; Hans-Jörg Hertfelder; Johannes Oldenburg; Peter Dreßen; Stefan Brettner; Jürgen Homann; Gerhard J Molderings
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

Review 8.  Mast cell glycosaminoglycans.

Authors:  B Mulloy; R Lever; C P Page
Journal:  Glycoconj J       Date:  2016-11-30       Impact factor: 2.916

Review 9.  Modern Imaging Technologies of Mast Cells for Biology and Medicine (Review).

Authors:  I P Grigorev; D E Korzhevskii
Journal:  Sovrem Tekhnologii Med       Date:  2021-08-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.